Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.35). The firm had revenue of ($1.02) million during the quarter, compared to the consensus estimate of $18.83 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. During the same quarter in the prior year, the firm posted $0.31 earnings per share. On average, analysts expect Amylyx Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX traded up $0.11 during trading hours on Tuesday, hitting $5.81. The company's stock had a trading volume of 787,893 shares, compared to its average volume of 2,026,456. The company has a market cap of $395.54 million, a price-to-earnings ratio of -2.33 and a beta of -0.70. The business has a 50 day simple moving average of $3.43 and a two-hundred day simple moving average of $2.44. Amylyx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $19.95.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMLX. Leerink Partners set a $4.00 target price on shares of Amylyx Pharmaceuticals and gave the company a "market perform" rating in a report on Friday, October 18th. Bank of America raised Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $4.20 to $10.00 in a report on Wednesday, October 23rd. HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a research report on Friday, October 18th. Finally, The Goldman Sachs Group raised their price objective on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a "neutral" rating in a research report on Friday, July 12th. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $14.57.

Insider Activity

In other Amylyx Pharmaceuticals news, Director George M. Milne, Jr. purchased 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The stock was bought at an average cost of $2.20 per share, for a total transaction of $220,000.00. Following the purchase, the director now directly owns 858,571 shares in the company, valued at $1,888,856.20. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Camille L. Bedrosian sold 11,442 shares of the firm's stock in a transaction on Monday, September 30th. The stock was sold at an average price of $3.20, for a total transaction of $36,614.40. Following the completion of the transaction, the insider now directly owns 143,801 shares in the company, valued at $460,163.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director George M. Milne, Jr. purchased 100,000 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The stock was purchased at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the purchase, the director now owns 858,571 shares in the company, valued at $1,888,856.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 11.70% of the company's stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.